A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors

This phase II study is a clinical study to explore the efficacy and safety of BL-B01D1 combined with PD-1 Monoclonal Antibody in patients with locally advanced or metastatic non-small cell lung cancer, nasopharyngeal carcinoma and other solid tumors.

Trial Details

NCT ID

NCT06475300

Phase

PHASE2

Sponsor

Sichuan Baili Pharmaceutical Co., Ltd.

Status

RECRUITING

Cancer Type

Lung Cancer

Interventions

BL-B01D1
PD-1 Monoclonal Antibody
Pemetrexed Disodium

Locations (sample)

Guangzhou, Guangdong, China|23.11667,113.25

Key Eligibility Criteria

Sign the informed consent form voluntarily and follow the protocol requirements;
Any gender;
Age: ≥18 years old;
Expected survival time for 3 months or more;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →